Disease modifying treatments for multiple sclerosis: What is on the horizon?

CNS Drugs

Volumn 11, Issue 2, 1999, Pages 133-157

  Weilbach, Franz X ^a   Gold, Ralf ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; BETA1A INTERFERON; CYTOKINE; ETRETINATE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGIC AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 1BETA CONVERTING ENZYME; LENERCEPT; LEXIPAFANT; METACYCLINE; OMEGA 6 FATTY ACID; PENTOXIFYLLINE; PHOSPHODIESTERASE IV INHIBITOR; PRALNACASAN; PROGESTERONE; RECOMBINANT ALPHA2A INTERFERON; ROLIPRAM; ROQUINIMEX; SELCID; TAU INTERFERON; TENEFUSE; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR BINDING PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR;

ANTIMICROBIAL THERAPY; CELL ADHESION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE IRRADIATION; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RECURRENT DISEASE; REMYELINIZATION; REVIEW; SYSTEMATIC DESENSITIZATION; TISSUE REPAIR;

EID: 0032911261     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199911020-00005     Document Type: Review

References (255)

1. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain 1997; 120: 865-916
2. Martin R, McFarland H. Experimental immunotherapies for multiple sclerosis. Springer Semin Immunopathol 1996; 18: 1-24
3. Raine CS. The Dale E. McFarlin Memorial Lecture: the immunology, of the multiple sclerosis lesion. Ann Neurol 1994; 36: S61-72
4. Lucchinetti CF, Bruck W, Rodriguez M, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996; 6: 259-74
5. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85
6. Wekerle H. Myelin specific, autoaggressive T cell clones in the normal immune repertoire: their nature and their regulation. Int Rev Immunol 1992; 9: 231-41
7. Berger T, Weerth S, Kojima K, et al. Experimental autoimmune encephalomyelitis: the antigen specificity of T lymphocytes determines the topography of lesions in the central and peripheral nervous system. Lab Invest 1997; 76: 355-64
8. Fujinami RS, Oldstone MB. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 1985; 230: 1043-5
9. Lehmann PV, Sercarz EE, Forsthuber T, et al. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 1993; 14: 203-8
10. Bruck W, Bitsch A, Kolenda H, et al. Inflammatory central nervous system demyclination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-93
11. Storch M, Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr Opin Neurol 1997; 10: 186-92
12. Miller DH, Grossman RI, Reingold SC, et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121: 3-24
13. Goodkin DE, Kinkel RP, Weinstock-Guttman B, et al. A randomized, double-masked, dose-comparison, phase II study or bimonthly intravenous methylprednisolone (IVMP) to modify progression of disability in patients with secondary progressive multiple sclerosis [abstract]. Neurology 1997; 48: A339-340
14. Noseworthy JH, Hopkins MB, Vandervoort MK, et al. An opentrial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993; 43: 1401-6
15. Krapf H, Morrissey SP, Zenker O, et al. Mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, randomized, observer-blind european phase III multicenter study-MRI results [abstract]. Mult Scler 1998; 4: 380
16. Zhao GJ, Li DK, Wolinsky JS, et al. Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. The MS Study Group. J Neuroimaging 1997; 7: 1-7
17. Goodkin DE, Rudick RA, VanderBrug-Medendorp S, et al. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology 1996; 47: 1153-7
18. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338: 1051-5
19. Cavazzuti M, Merelli E, Tassone G, et al. Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment: a retrospective study. Eur Neurol 1997; 38: 284-90
20. Beutler E, Sipe JC, Rominc JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 1996; 93: 1716-20
21. Bartlett RR, Anagnostopulos H, Zielinski T, et al. Effects of leflunomide on immune responses and models of inflammation. Springer Semin Immunopathol 1993; 14: 381-94
22. Kappos L, Radu EW, Haas J, et al. Deoxyspergualine in MS: a second interim analysis of the European multicentre study [abstract]. J Neurol 1995; 242 Suppl. 2: S23
23. Kappos L, Radu EW, Haas J, et al. European multicentre trial +/-deoxyspergualine (DSG) versus placebo: results of the first interim analysis [abstract]. J Neurol 1994; 241 Suppl. 2: S27
24. BioCryst Pharmaceuticals Inc. PNP Program [online]. Available from: URL: http://www.biocryst.com/PNP.htm [Accessed 1998 Dec 29]
25. Vertex Pharmaceuticals: press releases [online]. Available from: URL: http://www.vpharm.com/press_rel/1998_press/13January1998.html [Accessed 1998 Dec 29]
26. Lemster B, Huang LL, Irish W, et al. Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. Autoimmunity 1994; 19: 89-98
27. Angiotech Pharmaceuticals. Products [online]. Available from: URL: http://www.angiotech.com/rd/products.html [Accessed 1998 Dec 29]
28. 09) in active multiple sclerosis: preliminary report [abstract]. Neurology 1997; 48: A340
29. Llewellyn-Smith N, Lai M, Miller DH, et al. Effects of antiCD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412. Neurology 1997; 48: 810-6
30. Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multipie sclerosis. Brain 1996; 119: 225-37
31. Hale G, Phillips JM. Clinical trials with CAMPATH-1 and other monoclonal antibodies. Biochem Soc Trans 1995; 23: 1057-63
32. Current Drugs Ltd. Press release [online]. Available from: URL: http://www.current-drugs.com/news/press/idec.htm [Accessed 1998 Dec 29]
33. Pharmaceutical Research and Manufacturers of America. New medicines in development for neurologic disorders [online]. Available from: URL: http://www.phrma.org:80/pdf/charls/neuro.pdf [Accessed 1998 Dec 29]
34. Cook SD, Devereux C, Troiano R, et al. Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis. J Neurol Sci 1997; 152: 172-81
35. Comi G, Rodegher M, Colombo B, et al. Low-dose total body irradiation in chronic progressive multiple sclerosis: a double blind, controlled, randomized phase II study [abstract]. Neurology 1997; 48: A340
36. Amato MP, Pracucci G, Ponziani G, et al. Long-term safety of azathioprine therapy in multiple sclerosis. Neurology 1993; 43: 831-3
37. Confavreux C, Saddler P, Brimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case control study. Neurology 1996; 46: 1607-12
38. Hohlfeld R, Michels M, Heininger K, et al. Azathioprine toxicity during long-term immunosuppression or generalized myasthenia gravis. Neurology 1988; 38: 258-61
39. Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis [letter]. Lancet 1997; 350: 261
40. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-8
41. Goodkin DE, Rudick RA, VanderBrug-Medendorp S, et al. Lowdose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37: 30-40
42. MS-Net. Cladribine: company unsure about submission for approval [online]. Available front: URL: http://www.ms-network.com/msnetwork/ms-network/bb/view.htx?X_AID=2 54 [Accessed 1998 Apr 10]
43. Rudge P, Koetsier JC, Mertin J, et al. Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry 1989; 52: 559-65
44. The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990; 27: 591-605
45. Kappas L, Patzold U, Dommasch D, et al. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis - results of the German multicenter study. Ann Neurol 1988; 23: 56-63
46. Noseworthy JH, O'Brien P, Erickson BJ, et al. The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 1998; 51: 1342-52
47. Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996; 8: 710-20
48. Confavreux C, Moreau T. Emerging treatments in multiple sclerosis: azathioprine and mofetil. Mult Scler 1996; 1: 379-84
49. Wada Y, Yagihashi A, Terasawa K, et al. BCX-34: a novel T-cell selective immunosuppressant: purine nucleoside phosphorylase (PNP) inhibitor. Artif Organs 1996; 20: 849-52
50. van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cMT412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997; 49: 351-7
51. Rep MH, van Oosten BW, Roos MT, et al. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. J Clin Invest 1997; 99: 2225-31
52. Moreau T, Coles A, Wing M, et al. CAMPATH-IH in multiple sclerosis. Mull Scler 1996; 1: 357-65
53. Lorenz H-M, Kalden JR. Biological agents in rheumatoid arthritis. Which ones could be used in combination. Biopharmaceuticals 1998; 9: 303-24
54. Devereux CK, Vidaver R, Hafstein MP, et al. Total lymphoid irradiation for multiple sclerosis. Int J Radial Oncol Biol Phys 1988; 14: 197-203
55. Devereux C, Troiano R, Zito G, et al. Effect of total lymphoid irradiation on functional status in chronic multiple sclerosis: importance of lymphopenia early after treatment - the pros. Neurology 1988; 38: 32-7
56. Wiles CM, Omar L, Swan AV, et al. Total lymphoid irradiation in multiple sclerosis. J Neurol Neurosurg Psychiatry 1994; 57: 154-63
57. Cook SD, Devereux C, Troiano R, et al. Combination total lymphoid irradiation and low-dose corticosteroid therapy for progressive multiple sclerosis. Acta Neurol Stand 1995; 91: 22-7
58. Gold DP, Smith RA, Golding AB, et al. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide. J Neuroimmunol 1997; 76: 29-38
59. Wilson DB, Golding AB, Smith RA, et al. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations. J Neuroimmunol 1997; 76: 15-28
60. Chou YK, Morrison WJ, Weinberg AD, et al. Immunity to TCR peptides in multiple sclerosis. II T cell recognition of V beta 5.2 and V beta 6.1 CDR2 peptides. J Immunol 1994; 152: 2520-9
61. Bourdette DN, Whitham RH, Chou YK, et al. Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides. J Immunol 1994; 152: 2510-9
62. Vandenbark AA, Chou YK, Whitham R, et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med 1996; 2: 1100-15
63. Connectics Corporation. Products [online]. Available from: URL: http://www.connetics.com/ter.html [Accessed 1998 Dec 29]
64. AVANT Immunotherapeutics Inc. T Cell Sciences announces progress in phase I multiple sclerosis trial with Astra AB February 23, 1998 [online]. Available from: URL: http://www.avantimmune.com/ [Accessed 1998 Dec 29]
65. Neurocrine Biosciences Inc. NBI annual report-lead development programs [online]. Available from: URL: http://www.neurocrine.com/ir/ar/ar-APL.html [Accessed 1998 Dec 29]
66. Lindsey JW, Lublin FD, Stark SR, et al. Double-blind, randomized, placebo-controlled evaluation of the safety, tolerability and pharmacokinetics of CGP 77116 in patients with multiple sclerosis [abstract]. Neurology 1998; 50: A139
67. Gaur A, Boehme SA, Chalmers D, et al. Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myclin basic protein peptides, involves different cellular mechanisms. J Neuroimmunol 1997; 74: 149-58
68. Vergelli M, Hemmer B, Kalbus M, et al. Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells. J Immunol 1997; 158: 3746-52
69. Health Care News Feinstein Kean Partners Inc. Peptimmune and Peptide Therapeutics Group enter collaborative agreement to develop Cathepsin S. inhibitors to treat asthma, autoimmune diseases [online]. Available from: URL: http://www.fkpi.com/Release_Comp/Releases/Peptimmune/3-17-98.html [Accessed 1998 Dec 29]
70. Samson MF, Smilek DE. Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myclin basic protein peptide analogue modified to form long-lived peptide-MHC complexes. J Immunol 1995; 155: 2737-46
71. Elliott EA, McFarland HI, Nye SH, et al. Treatment of experimental encerphalomyclitis with a novel chimeric fusion protein or myclin basic protein and proteolipid protein. J Clin Invest 1996; 98: 1602-12
72. Warren KG, Catz I. Administration of myclin basic protein synthetic peptides to multiple sclerosis patients. J Neurol Sci 1995; 133: 85-94
73. Briana Bio-Tech Inc. Briann licenses multiple sclerosis technology [online]. Available from: URL: http://www.brianabiotech.com/news97/100997.html [Accessed 1998 Dec 29]
74. AutoImmune Inc. In the Clinic-Myloral® [online]. Available from: URL: http://www.autoimmuneine.com/clinic/myloral.html [Accessed 1998 Dec 29]
75. Panitch HG, Francis G, and the Oral myclin Study Group. Clinical results of a phase III trial of oral myclin in relapsing-remitting multiple sclerosis [abstract]. Ann Neurol 1997; 44: 459
76. Hafler DA, Cohen I, Benjamin DS, et al. T cell vaccination in multiple sclerosis: a preliminary report. Clin Immunol Immunopathol 1992; 62: 307-13
77. Slinissen P, Zhang J, Medaer R, et al. Vaccination with autoreactive T cell clones in multiple sclerosis: overview of immunological and clinical data. J Neurosci Res 1996; 45: 500-11
78. Moviglla GA, Varela O, Memolli M, et al. Lymphocyte autovaccine for multiple sclerosis and other demyclinating autoimmune diseases: results of a phase I-II clinical trial [abstract]. Ann Neurol 1997; 44: 461
79. Correale J, McMillan M, McCarthy K, et al. T cell vaccination in multiple sclerosis: results of a phase I clinical trial [abstract]. Neurology 1998; 50: A63
80. Spack EG. Treatment of autoimmune diseases through manipulation of antigen preparation. Crit Rev Immunol 1997; 17: 529-36
81. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer I Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-76
82. Liblau R, Tisch R, Bercovici N, et al. Systemic antigen in the treatment of T-cell-mediated autoimmune diseases. Immunol Today 1997; 18: 599-604
83. Wether HL, Friedman A, Miller A, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994; 12: 809-37
84. Francis G, Evans A, Panitch H. MRI Results of a phase III trial of oral myclin in relapsing-remitting multiple sclerosis [abstract]. Ann Neurol 1997; 42: 467
85. Panitch H, Francis G. and the Oral myclin Study Group. Clinical Results or a phase III trial of oral myclin in relapsing-remitting multiple sclerosis [abstract]. Ann Neurol 1997; 42: 459
86. Barnett ML, Kremer JM, St Clair EW, et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1998; 41: 290-7
87. Zhang J, Raus J. T cell vaccination in multiple sclerosis: hopes and facts. Acta Neurol Belg 1994; 94: 112-5
88. Nicholson LB, Greer JM, Sobel RA, et al. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995; 3: 397-405
89. Nicholson LB, Kuchroo VK. T cell recognition of self and altered self antigens. Crit Rev Immunol 1997; 17: 449-62
90. Wincihagen A, Scholz C, Höllsbert P, et al. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution or their peptide ligand. Immunity 1995; 2: 373-80
91. Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993; 363: 156-9
92. Teitelbaum D, Milo R, Amon R, et al. Synthetic copolymer I inhibits human T-cell lines specific for myclin basic protein. Proc Natl Acad Sci USA 1992; 89: 137-41
93. Bornstein MB, Miller A, Single S, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop I in chronic progressive multiple sclerosis. Neurology 1991; 41: 533-9
94. Racke MK, Martin R, McFarland H, et al. Copolymer-I-induced inhibition of antigen-specific T cell activation: interference with antigen presentation. J Neuroimmunol 1992; 37: 75-84
95. Teitelbaum D, Aharoni R, Amon R, et al. Specific inhibition of the T-cell response to myclin basic protein by the synthetic copolymer Cop I. Proc Natl Acad Sci USA 1988; 85: 9724-8
96. Mancardi GL, Sardanelli F, Parodi RC, et al. Effect of copolymer-I on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 1998; 50: 1127-33
97. Johnson KP and the US Phase III Copolymer I Study Group. Antibodies to copolymer I do not interfere with its clinical effect [abstract]. Ann Neurol 1995; 38: 973
98. Chluba J, Steeg C, Becker A, et al. T cell receptor beta chain usage in myclin basic protein-specific rat T lymphocytes. Eur J Immunol 1989; 19: 279-84
99. Howell MD, Winters ST, Olec T, et al. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 1989; 246: 668-70
100. Vandenbark AA, Bourdette DN, Whitham R, et al. T-cell receptor peptide therapy in EAE and MS. Clin Exp Rheumatol 1993; 11: S51-3
101. Kotzin BL, Karuturi S, Chou YK, et al. Preferential T-cell receptor beta-chain variable gene use in myclin basic proteinreactive T-cell clones from patients with multiple sclerosis. Proc Natl Acad Sci USA 1991; 88: 9161-5
102. Giegerich G, Pette M, Meinl E, et al. Diversity of T cell receptor alpha and beta chain genes expressed by human T cells specific for similar myclin basic protein peptide/major histocompatibility complexes. Eur J Immunol 1992; 22: 753-8
103. Gold R, Giegerich G, Hartung HP, et al. T-cell receptor (TCR) usage in Lewis rat experimental autoimmune encephalomyelitis: TCR beta-chain-variable-region V beta 8.2-positive T cells are not essential for induction and course of disease. Proc Natl Acad Sci USA 1995; 92: 5850-4
104. Selmaj KW, Raine CS. Tumor necrosis factor mediates myclin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23: 339-46
105. Calabresi PA, Fields NS, Maloni HW, et al. Phase I trial of transforming growth factor beta 2 in chrome progressive MS. Neurology 1998; 51: 289-92
106. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 443-50
107. Celgene. IMiDs [online]. Available from: URL: http://www.celgene.com/Imids.htm [Accessed 1998 Dec 29]
108. Sommer N, Löschmann PA, Northoff GH, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmunc encephalomyelitis. Nat Med 1995; 1: 244-8
109. Rieckmann P, Weber F, Gunther A, et al. Pentoxifylline, a prosphodiestense inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 1996; 64: 193-200
110. Friedman JE, Zabriskie J, Bourganskaia E. A pilot study of pentoxifylline in multiple sclerosis. Arch Neurol 1996; 53: 956-7
111. van Oosten BW, Rep MH, van Lief RA, et al. A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. J Neuroimmunol 1996; 66: 49-55
112. Andersen O, Lycke J, Tollesson PO, et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996; 47: 895-900
113. Karussis DM, Meiner Z, Lehmann D, et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996; 47: 341-6
114. Lehmann D, Karussis D, Mizrachi-Koll R, et al. Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4+/CD45RA+ cells and downregulation of CD4+/CD45RO+ cells. Clio Immunol Immunopathol 1997; 85: 202-9
115. Celgene. SelCIDs [online]. Available from: URL: http://www.celgene.com/selcids.htm [Accessed 1998 Dec 29]
116. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-4
117. Advanced Biotherapy Concepts Inc. News release [online]. Available from: URL: http://www.worldcorporatereport.com/abei/corp.htm [Accessed 1998 Dec 29]
118. SG Cowen Securities Corporation. British Biotech [online]. Available from: URL: http://www.cowen.com/rs/biopipe/bbioy.htm [Accessed 1998 Dec 29]
119. British Biotech Inc. British Biotech homepage [online]. Available from: URL: http://www.britbio.com/overview.html [Accessed 1998 Dec 29]
120. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to turnout necrosis factor-alpha in Crohn's disease. Lancet 1997; 349: 521-4
121. Klinkert WE, Kojima K, Lesslauer W, et al. TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyclination in Lewis rats: an overview. J Neuroimmunol 1997; 72: 163-8
122. Renzetti LM, Paciorek PM, Tannu SA, et al. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways. J Pharmacol Exp Ther 1996; 278: 847-53
123. Korner H, Goodsall AL, Lemckert FA, et al. Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1995; 92: 11066-70
124. Chernoff AE, Granowitz EV, Shapiro L, et al. A randomized, controlled trial of IL-10 in humans: inhibition of inflammatory, cytokine production and immune responses. J Immunol 1995; 154: 5492-9
125. Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals disease targets: VX-740 (ICE) for inflammatory diseases [online]. Available from: URL: http://www.vpharm.com/disease_targ/ice.html [Accessed 1998 Dec 29]
126. Pan Y, Lloyd C, Zhou H, et al. Neurotactin, a membrane-an-chored chemokine upregulated in brain inflammation. Nature 1997; 387: 611-7
127. LeukoSite Inc. LeukoSite research and drug discovery programs [online]. Available from: URL: http://www.leukosite.com/rd/rd.html [Accessed 1998 Dec 29]
128. IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85
129. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7
130. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504
131. Comi G, Barkhof F, Durelli L, et al. Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study. Mult Scler 1995; 1: S24-7
132. Jacobs LD, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler 1995; 1: 118-35
133. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon bela-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94
134. Viragen press release June 17 1998. Viragen highlights progress at BIO '98 [online]. Available from: URL: http://www.viragen.com/virpr061798.htm [Accessed 1998 Dec 29]
135. Khan OA, Jiang H, Subramaniam PS, et al. Immunomodutating functions of recombinant ovine interferon tau: potential for therapy in multiple sclerosis and autoimmune disorders. Mult Scler 1998; 4: 63-9
136. Bongioanni MR, Durelli L, Ferrero B, et al. Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis. J Neurol Sci 1996; 143: 91-9
137. The University of Chicago Department of Neurology. Clinical drug trials [online]. Available from: URL: http://drugs.bsd.uchicago.edu/̃neurowww/trials.html [Accessed 1998 Dec 20]
138. Harbige LS, Layward L, Morris M, et al. Protective mechanisms by omega-6 lipids in experimental autoimmune encephalomyelitis (EAE) are associated with cytokines and eicosanoids. Biochem Soc Trans 1997; 25: 342S
139. P\S\L Consulting Group Inc. BSI CONGRESS: Promising fatty acid research leads to MS clinical trial [online]. Available from: URL: http://www.pslgroup.com/dg/4b762.htm [Accessed 1998 Dec 29]
140. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis Factor therapy abrogates autoimmune demyelination. Ann Neurol 1991; 30: 694-700
141. Renno T, Krakowski M, Piccirillo C, et al. TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis: regulation by Thl cytokincs. J Immunol 1995; 154: 944-53
142. Probert L, Akassoglou K, Pasparakis M, et al. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci USA 1995; 92: 11294-8
143. Liu J, Marino MW, Wong G, et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998; 4: 78-83
144. Cannella B, Rathe CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995; 37: 424-35
145. Brosnan CF, Cannella B, Battistini L, et al. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995; 45: S16-21
146. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996; 81: 219-23
147. Gonzalo JA, Gonzalez-Garcia A, Kalland T, et al. Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol 1993; 23: 2372-4
148. Jung S, Zielasek, J Köllner G, et al. Preventive but not therapeutic application of rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol 1996; 68: 1-11
149. Genain CP, Roberts T, Davis RL, et al. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA 1995; 92: 3601-5
150. Lawrence DA. Transforming growth factor-beta: a general review. Eur Cytokine Netw 1996; 7: 363-74
151. Schluesener HJ, Lider O. Transforming growth factors beta 1 and beta 2: cytokines with identical immunosuppressive effects and a potential role in the regulation of autoimmune T cell function. J Neuroimmunol 1989; 24: 249-58
152. Racke MK, Cannella B, Albert P, et al. Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis. Int Immunol 1992; 4: 615-20
153. Salmaggi A, Dufour A, Eoli M, et al. Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression? J Neurol 1996; 243: 13-7
154. Porrini AM, Gambi D, Reder AT. Interferon effects on interleukin-10 secretion: mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol 1995; 61: 27-34
155. Arnason BGW, Reder AT. Interferons and multiple sclerosis. Clin Neuropharm 1994; 17: 495-547
156. Leppert D, Waubant E, Burk MR, et al. InterFeron beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 846-52
157. Jiang H, Williams GJ, Dhib-Jalbut S. The effect oF interferon beta-lb on cytokine-induced adhesion molecule expression. Neurochem Int 1997; 30: 449-53
158. Hun LL, Liu JS, Brosnan CF, et al. Selective inhibition of human glial inducible nitric oxide synthase by interferon-beta: implications for multiple sclerosis. Ann Neurol 1998; 43: 384-7
159. Jacobs LD, CookFair DL, Rudick RA, et al. Intramuscular interferon beta-1a For disease progression in relapsing multiple sclerosis, The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94
160. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994; 44: 406-13
161. Brod SA, Kerman RH, Nelson LD, et al. Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis. Mult Scler 1997; 3: 1-7
162. Soos JM, Mujtaba MG, Subramaniam PS, et al. Oral feeding of interferon tau can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis. J Neuroimmunol 1997; 75: 43-50
163. Soos JM, Subramaniam PS, Hobeika AC, et al. The IFN pregnancy recognition hormone IFN-tau blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J Immunol 1995; 155: 2747-53
164. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Anna Rev Immunol 1997; 15: 675-705
165. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-45
166. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-14
167. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272: 60-6
168. Taub DD, Ortaldo JR, Turcovski-Corrales SM, et al. Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol 1996; 59: 81-9
169. Lukacs NW. Cytokines in allergic eosinophilic airway inflammation. Biol Signals 1996; 5: 209-14
170. Kunkel SL, Lukacs N, Kasama T, et al. The role of chemokines in inflammatory joint disease. J Leukoc Biol 1996; 59: 6-12
171. Icos Corp. Ions: pipeline [online]. Available from: URL: http://www.icos.com/pipeline/index.html [Accessed 1998 Dec 29]
172. Vanderslice P, Ren K, Revelle JK, et al. A cyclic hexapeptide is a potent antagonist of alpha 4 integrins. J Immunol 1997; 158: 1710-8
173. Business Wire 1998, Cytel Corporation receives patent for VLA-4 integrin blocking compounds; notice of allowance received for VLA-4 inhibiting antibodies [online]. Available from: URL: http://www.businesswire.com/webbox/bw.010998/572483.htm [Accessed 1998 Dec 29]
174. Bennett CF, Kornbrust D, Henry S, et al. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J Pharmacol Exp Ther 1997; 280: 988-1000
175. Henry SP, Taylor J, Midgley L, et al. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev 1997; 7: 473-81
176. Abraham WM, Ahmed A, Sielczak MW, et al. Blockade of late phase airway responses and airway hyperresponsiveness in allergic sheep with a small-molecule peptide inhibitor of VLA-4. Am J Respir Crit Care Med 1997; 156: 696-703
177. Leger OJ, Yednock TA, Tanner L, et al. Humanization of mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 1997; 8: 3-16
178. Consortium of Multiple Sclerosis Centers. MS research: clinical trials-open [online]. Available from: URL: http://info.med.yale.edu/cmsc/research/acute_exacer.html [Accessed 1998 Dec 29]
179. T Cell Sciences. T cell sciences receives U.S. patent allowance for sCRIsLex [online]. Available from: URL: www.tcell.com/graphic_browser/press_releases/022098.html [Accessed 1998 Dec 29]
180. UCSF-Mt Zion MS Center. Research projects [online]. Available from: URL: http://mscenter.his.ucsf.edu/research.html [Accessed 1998 Dec 29]
181. Dubois B, D'Hooghe MB, De Lepeleire K, et al. Toxicity in a double-blind, placebo-controlled pilot trial with D-penicillamine and metacycline in secondary progressive multiple sclerosis. Mult Scler 1998; 4: 74-8
182. Achiron A, Pras E, Gilad R, et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol 1992; 49: 1233-6
183. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997; 349: 589-93
184. Fazekas F, Dcisenhammer F, Strasser-Fuchs S, et al. Treatment effects of monthly intravenous immunoglebulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study. Mult Scler 1997; 3: 137-41
185. Poehlau D, Federlein J, Postert T, et al. Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis - outline of a double-blind randomized, placebo-controlled trial. Mult Scler 1997; 3: 149-52
186. Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G. reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50: 1273-81
187. Sorensen PS, Wanscher B, Schreiber K, et al. A double-blind, cross-over trial of intravenous immunoglobolin G in multiple sclerosis: preliminary results. Mult Scler 1997; 3: 145-8
188. Francis GS, Freedman MS, Antel JP. Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Mult Scler 1997; 3: 370-376
189. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 1998; 50: 398-402
190. Burt RK, Traynor AE, Cohen B, et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant 1998; 21: 537-41
191. Lycke J, Svennerholm B, Hjelmquist E, et al. Acyclovir treatment of relapsing-remitting multiple sclerosis: a randomized, placebo-controlled, double-blind study. J Neurol 1996; 243: 214-24
192. CenterWatch Inc. Trial #7304, Multiple Sclerosis, New York, NY [online]. Available from: URL: http://www.centerwatch.com/studies/STU7304.HTM [Accessed 1998 Dec 29]
193. Steiner JP, Connolly MA, Valentine HL, et al. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nat Med 1997; 3: 421-8
194. Steiner JP, Hamilton GS, Ross DT, et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci USA 1997; 94: 2019-24
195. Guilford Pharmaceuticals Inc. Neuroimmunophilin Program [online]. Available from: URL: http://www.guilfordpharm.com/products/neurotrp.htm [Accesed 1998 Dec 29]
196. NIH Clinical Research Studies. Clinical study: 97-N-0148 [online]. Available from: URL.: http://www/cc.nih.gov/cc/bin/clinicalstudies/wais/bold.pl?/u/pfreling/www/studie s/detail/A_97-N-0148.html@multiple@sclerosis [Accessed 1998 Dec 29]
197. PR Newswire. Neurocrine Biosciences discovers new small molecule growth factor technology [online]. Available from: URL: http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=105&STORY=/www/story/2-16- 98/416284&EDATE= [Accessed 1998 Dec 29]
198. Lee SJ. Identification of a novel member (GDF-1) of the transforming growth factor-beta superfamily. Mol Endocrinol 1990; 4: 1034-40
199. Cannella B, Hoban CJ, Gao YL, et al. The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis. Proc Natl Acad Sci USA 1998; 95: 10100-5
200. Cambridge NeuroScience Inc. Technology & trials. Glial growth Factor project [online]. Available from: URL: http://www.cambneuro.com/tech/ggf.htm#anchor248739 [Accessed 1998 Dec 29]
201. Baulieu EE, Schumacher M, Koenig H, et al. Progesterone as a neurosteroid: actions within the nervous system. Cell Mol Neurobiol 1996; 16: 143-54
202. Hartung HP, Reiners K, Archelos JJ, et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 1995; 38: 186-93
203. Martin S, Rieckmann P, Melchers I, et al. Circulating forms of ICAM-3 (cICAM-3). Elevated levels in autoimmune diseases and lack of association with cICAM-I. J Immunol 1995; 154: 1951-5
204. Matsuda M, Tsukada N, Miyagi K, et al. Increased levels of soluble vascular cell adhesion molecule-I (VCAM-l) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-l-associated myelopathy. J Neuroimmunol 1995; 59: 35-40
205. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta I integrin. Nature 1992; 356: 63-6
206. Archelos JJ, Jung S, Maurer M, et al. Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-I. Ann Neurol 1993; 34: 145-54
207. Gordon EJ, Myers KJ, Dougherty JP, et al. Both anti-CDIIa (LFA-I) and anti-CDIlb (MAC-I) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 1995; 62: 153-60
208. Kent SJ, Karlik SJ, Cannon C, et al. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995; 58: 1-10
209. Anthony DC, Ferguson B, Matyzak MK, et al. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 1997; 23: 406-15
210. Gearing AJ, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994; 370: 555-7
211. Liedtke W, Cannella B, Mazzaccaro RJ, et al. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann Neurol 1998; 44: 35-46
212. Hewson AK, Smith T, Leonard JP, et al. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 1995; 44: 345-9
213. Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997; 126: 721-30
214. Stangel M, Hartung HP, Marx P, et al. Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci 1998; 153: 203-14
215. Cook SD, Troiano R, Rohowsky-Kochan C, et al. Intravenous gamma globulin in progressive MS. Acta Neurol Scand 1992; 86: 171-5
216. Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 1990; 27: 12-7
217. Noseworthy JH, Weinshenker BG, O'Brien PC, et al. Intravenous immunoglobulin does not reverse recently acquired, apparently permanent weakness in multiple sclerosis [abstract]. Ann Neurol 1997; 42: 421
218. van Engelen BG, Hommes OR, Pinckers A, et al. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 1992; 32: 834-5
219. Burt RK, Burns W, Hess A. Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplant 1995; 16: 1-6
220. McAllister ID, Beatty PG, Rose J. Allogeneic bone marrow transplant for chronic myclogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant 1997; 19: 395-7
221. van Gelder M, van Bekkum DW. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transplant 1996; 18: 1029-34
222. van Gelder M, van Bekkum DW. Treatment of relapsing experimentalautoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain. Bone Marrow Transplant 1995; 16: 343-51
223. Brodsky RA, Petri M, Smith BD, et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 1998; 129: 1031-5
224. Cook SD, Rohowsky-Kochan C, Bansil S, et al. Evidence for multiple sclerosis as an infectious disease. Acta Neurol Scand Suppl. 1995; 161: 34-42
225. Soldan SS, Berti R, Salem N, et al. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med 1997; 3: 1394-7
226. Prineas JW, Barnard RO, Kwon EE, et al. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993; 33: 137-51
227. Noble M, Wolswijk G. Development and regeneration in the O-2A lineage: studies in vitro and in vivo. J Neuroimmunol 1992; 40: 287-93
228. Compston A. Remyelination in multiple sclerosis: a challenge for therapy. The 1996 European Charcot Foundation Lecture. Mult Scler 1997; 3: 51-70
229. Liu X, Linington C, Webster HD, et al. Insulin-like growth factor-I treatment reduces immune cell responses in acute nondemyelinative experimental autoimmune encephalomyelitis. J Neurosci Res 1997; 47: 531-8
230. Yao DL, Liu X, Hudson LD, et al. Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1995; 92: 6190-4
231. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997; 42: 379-82
232. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996; 39: 6-16
233. Hughes RA, Sharrack B. More immunotherapy for multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 61: 239-41
234. Milo R, Panitch H. Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein. J Neuroimmunol 1995; 61: 185-93
235. Qu ZX, Dayal A, Jenson MA, et al. All-trans retinoic acid potentiates the ability of interferon beta-1b to augment suppressor cell function in multiple sclerosis. Arch Neurol 1998; 55: 315-21
236. Elliott EA, Cofiell R, Wilkins JA, et al. Immune tolerance mediated by recombinant proleolipid protein prevents experimental autoimmune encephalomyelitis. J Neuroimmunol 1997; 79: 1-11
237. Branisteanu DD, Mathieu C, Casteels K, et al. Combination of vitamin D analogues and immunosuppressants. Clin Immunother 1996; 6: 465-478
238. Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals disease targets: MAP kinases [online]. Available from: URL: http://www.vpharm.com/disease_targ/mapkinases.html [Accessed 1998 Dec 29]
239. Balashov KE, Smith DR, Khoury SJ, et al. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Aced Sci USA 1997; 94: 599-603
240. Shaw MK, Lorens JB, Dhawan A, et al. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J Exp Mod 1997; 185: 1711-4
241. Carballo E, Gilkeson GS, Blackshear PJ. Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (-/-) mice. Evidence that monocyte/macrophage progenitors may be responsible lox TNFalpha overproduction. J Clin Invest 1997; 100: 986-95
242. Carballo E, Lai WS, Blackshear PJ. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 1998; 281: 1001-5
243. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996; 93: 7861-4
244. Hayes CE, Cantorna MT, DeLuca HF. Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med 1997; 216: 21-7
245. Vergelli M, Olivotto J, Castigli E, et al. Immunsosuppressive activity of 13-cis-retinoic acid in rats: aspects of pharmacokinetics and pharmacodynamics. Immunopharmacology 1997; 37: 197-7
246. Hooper DC, Spitsin S, Keen RB, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1998; 95: 675-80
247. Aikawa Y, Tanuma N, Shin T, et al. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis. J Neuroimmunol 1998; 89: 35-42
248. Croxford JL, Triantaphyllopoulos K, Podhajcer OL, et al. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J Immunol 1998; 160: 5181-7
249. Triantaphyllopoulos K, Croxford J, Baker D, et al. Cloning and expression of murine IFN beta and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis. Gene Ther 1998; 5: 253-63
250. Croxford JL, O'Neill JK, Ali RR, et al. Local gene therapy with CWLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis. Eur J Immunol 1998; 28: 3904-16
251. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52
252. Glover JM, Leeds JM, Mant TFK, et al. Phase I safety and phamacokinetic profile of an intercellular adhesion molecule-1 antisense oligonucleotide (Isis 2302). J Pharmacol Exp Ther 1997; 282: 1173-80
253. Waisman A, Ruiz PJ, Hirschberg DL, et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat Med 1996; 2: 899-905
254. Youssef S, Wildbaum G, Maor G, et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J Immunol 1998; 161: 3870-9
255. Nelson PA, Akselband Y, Dearborn SM, et al. Effect of oral beta interferon on subsequent immune responsiveness. Ann N Y Acad Sci 1996; 778: 145-55